

Statins in Liver Disease: Oh the Pain!

Alina Plavsky, MD, MPH Sima Desai, MD

Department of Medicine, Oregon Health & Science University

Case Presentation

HPI: A 42-year-old female with cryptogenic cirrhosis, Type II diabetes mellitus, hyperlipidemia, pancytopenia, and awaiting liver transplant presents with acute progressive myalgias and proximal muscle weakness with dark urine over five days. Review of systems was negative for fever and upper respiratory symptoms, but positive for a recent sick contact and increase in atorvastatin dosing a month prior.

Medications:

- atorvastatin 40 mg daily
- insulin glargine
- insulin aspart
- Vitamin D3
- furosemide
- lactulose oral solution
- metformin
- spironolactone

Social History:

- remote drinking history
- no IVDU
- no other drug use

Physical Exam:

- Vital signs: normal (BP 106/90 mmHg)
- HEENT: scleral icterus
- MSK: moderate tenderness of bilateral thighs, calf muscles, shoulders
- Neurologic: 4 / 5 UE and LE proximal muscle weakness

Labs:

- CK **7500 U/L**
- chronic pancytopenia
- normal electrolytes except K 3.1 mmol/L
- Cr 1.32 mg/dL (prior 0.6 mg/dL)
- AST 540 U/L, ALT 135 U/L, AP 297 U/L
- Total bilirubin 7.0 mg/dL
- albumin 1.5 g/dL
- normal ESR, CRP, and thyroid function

Other tests:

 Viral testing negative for adenovirus, coronavirus, metapneumovirus, influenza A/B, parainfluenza, RSV, Bordetella pertussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, rhinovirus/enterovirus, HIV, CMV, and EBV.

Brief Hospital Course

She was admitted for management of rhabdomyolysis and treated with aggressive IV hydration. After hydration, patient had return of muscle strength, CK levels gradually improved, and her renal function normalized.





Figure 1. Scheme for statin-induced rhabdomyolysis. ER: endoplasmic reticulum, GGPP: geranylgeranylpyrophosphate, GG-Rab: geranylgeranylated Rab GTPase, MMP: mitochondrial membrane potential, OATP: organic anion transporting polypeptide, PM: plasma membrane. ³

References

- 1. Benmassaoud, Amine, and Emmanuel A. Tsochatzis. "The Use of Statins in the Management of Chronic Liver Disease." AME Medical Journal, vol. 3, 2018, pp. 3–3. doi:10.21037/amj.2017.12.07.
- 2. Kumar, Sonal, et al. "Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study." Digestive Diseases and Sciences, vol. 59, no. 8, 2014, pp. 1958–1965. doi:10.1007/s10620-014-3179-2.
- 3. Sakamoto, Kazuho, and Junko Kimura. "Mechanism of Statin-Induced Rhabdomyolysis." Journal of Pharmacological Sciences, vol. 123, no. 4, 26 Sept. 2013, pp. 289–294. doi:10.1254/jphs.13r06cp.
- 4. Vargas, Jose Ignacio, et al. "Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects." Current Gastroenterology Reports, vol. 19, no. 9, 2017. doi:10.1007/s11894-017-0584-7.

Discussion

- Statins can lead to rhabdomyolysis by inhibiting HMG-CoA reductase. This causes a decrease in mitochondrial ATP synthesis and an increase in proteolysis, leading to muscular weakness.
- Myalgias from statin use occur in 1-10% of the general population, while rhabdomyolysis occurs less than 0.1% of the time. The risk is dose-dependent.
- However, routine monitoring of liver enzymes is ineffective in assessing who will develop liver injury from statin therapy.
- Decompensated liver cirrhosis and acute liver failure are still contraindications to statin use.
- On the other hand, patients with **liver disease** have an increased risk of **cardiovascular disease**.
- Statins also slow progression of fibrosis, prevent hepatic decompensation, and may **reduce all-cause mortality** in patients with chronic liver disease.
- Overall, statin therapy in patients with chronic liver disease is likely more beneficial than harmful.



Teaching Points

Teaching point 1:

 Rhabdomyolysis is a rare complication of statin therapy.

Teaching point 2:

• Clinicians should be aware of the potential increase in the use for patients with cirrhosis due to reduction in cardiovascular disease and all-cause mortality. The overall benefit likely outweighs the risk.